Skip to main content

Table 1 Patient characteristics and comparison of tumor uptake of fludeoxyglucose/18F-fluoromisonidazole

From: Intracellular hypoxia measured by 18F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer

    

FDG-SUVmax

FMISO-TBR

Variables

 

Number

(%)

Mean

SD

p Value

Mean

SD

p Value

Number of patients

 

44

       

Age, years

Average

53.5

       

(range)

(38–78)

       

< 50

20

(45.4)

11.1

4.4

0.02

1.3

0.4

0.3

≥ 50

24

(45.5)

7.9

4.2

1.2

0.4

Tumor size

Average

40.9

       

(range)

(14–80)

       

< 4 cm

25

(56.8)

8

3.6

0.02

1.1

0.4

0.03

≥ 4 cm

19

(43.1)

11.1

5.1

1.4

0.4

Histology

IDC

41

(93.1)

9.6

4.4

0.1

1.2

0.4

0.9

Others

3

(6.8)

6

3.5

1.2

0.7

Nuclear grade

1/2

17

(38.6)

7.4

3.6

0.06

1

0.2

0.007

3

21

(47.7)

10

4.7

1.4

0.5

Unknown

6

(13.6)

–

  

–

–

 

Nodal involvement

0

12

(27.2)

6.8

3.3

0.01

1.2

0.4

0.9

≥ 1

32

(72.7)

10.5

4.6

1.2

0.4

ER

+

26

(59)

9.1

4.2

0.7

1.1

0.3

0.04

–

18

(40.9)

9.6

5.1

1.4

0.5

PgR

+

19

(43.1)

7.9

3.1

0.07

1

0.2

0.009

–

25

(56.8)

10.4

5.2

1.4

0.5

HER2

+

7

(15.9)

7.8

3.6

0.3

1.2

0.2

1

–

37

(84)

9.6

4.7

1.2

0.4

Luminal A

 

7

(15.9)

7.8

2.5

0.4

0.9

0.2

0.03

Luminal B

 

16

(36.4)

9.7

4.8

1.1

0.3

TNBC

 

14

(31.8)

10.5

5.4

1.4

0.5

HER2

 

7

(15.9)

7.9

3.6

1.2

0.2

Chemotherapy

+

39

(88.6)

9.7

4.6

0.1

1.2

0.4

0.01

–

5

(11.4)

6.4

3

0.7

0.1

Endocrine therapy

+

26

(59)

9.1

4.2

0.7

1.1

0.3

0.04

–

18

(40.9)

9.6

5.1

1.4

0.5

  1. Abbreviations: FDG 18F-fluorodeoxyglucose, FMISO 18F-fluoromisonidazole, IDC Invasive ductal carcinoma, ER Estrogen receptor, PgR Progesterone receptor, TBR Tissue-to-blood ratio, TNBC Triple-negative breast cancer, HER2 Human epidermal growth factor receptor 2, SUVmax Maximum standardized uptake value